Intech Investment Management LLC Acquires Shares of 32,848 Guardant Health, Inc. (NASDAQ:GH)

Intech Investment Management LLC bought a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 32,848 shares of the company’s stock, valued at approximately $754,000.

A number of other large investors also recently made changes to their positions in GH. Sumitomo Mitsui Trust Group Inc. grew its position in Guardant Health by 1,282.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock worth $28,128,000 after purchasing an additional 1,137,482 shares in the last quarter. First Light Asset Management LLC boosted its stake in shares of Guardant Health by 119.7% in the 2nd quarter. First Light Asset Management LLC now owns 416,967 shares of the company’s stock worth $12,042,000 after buying an additional 227,202 shares during the last quarter. International Assets Investment Management LLC grew its holdings in shares of Guardant Health by 2,193.9% in the third quarter. International Assets Investment Management LLC now owns 10,208 shares of the company’s stock valued at $2,340,000 after acquiring an additional 9,763 shares in the last quarter. Sei Investments Co. purchased a new stake in shares of Guardant Health during the second quarter valued at approximately $831,000. Finally, SG Americas Securities LLC bought a new stake in Guardant Health during the third quarter worth $1,029,000. 92.60% of the stock is owned by institutional investors.

Insider Activity at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. TD Cowen upped their price objective on Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Sanford C. Bernstein reduced their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Craig Hallum lifted their price objective on shares of Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. The Goldman Sachs Group increased their target price on shares of Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Leerink Partners lowered their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and an average target price of $40.60.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $35.61 on Friday. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $37.04. The stock has a market cap of $4.40 billion, a PE ratio of -8.28 and a beta of 1.11. The stock has a fifty day moving average of $25.00 and a 200-day moving average of $27.26.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company had revenue of $191.48 million for the quarter, compared to analysts’ expectations of $170.49 million. During the same period in the previous year, the firm earned ($0.73) EPS. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. Equities research analysts anticipate that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.